18 research outputs found

    Alirocumab and cardiovascular outcomes after acute coronary syndrome

    No full text
    BACKGROUN

    Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

    No full text
    BACKGROUN

    Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial

    No full text

    Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial

    No full text

    Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome

    No full text

    Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

    No full text

    Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events The ODYSSEY OUTCOMES Trial

    No full text

    Risk categorization using New American College of Cardiology/American Heart Association guidelines for cholesterol management and its relation to alirocumab treatment following acute coronary syndromes

    No full text

    Alirocumab in patients with polyvascular disease and recent acute coronary syndrome ODYSSEY OUTCOMES trial

    No full text
    corecore